Literature DB >> 2922891

Immunological aspects of intravesical administration of Bacillus Calmette-Guérin (BCG) in the guinea pig.

A P van der Meijden1, W H de Jong, E C de Boer, P A Steerenberg, F M Debruyne, E J Ruitenberg.   

Abstract

The only form of effective immunotherapy for human cancer is the intravesical administration of BCG in the treatment of superficial bladder tumors. In this study BCG was administered intravesically (once a week for six consecutive weeks) in guinea pigs to investigate the immune response. Both specific immune responses against BCG itself and nonspecific immune responses such as leukocyte subset distribution, mitogenic (ConA, PHA, LPS) lymphocyte stimulation and spontaneous cytotoxic (NK and LAK cell) activity were determined in the regional draining (iliac) lymph node and in the spleen. The PPD skin test became positive after the fourth intravesical instillation of BCG when 1 X 10(5) culturable particles or higher dosages of BCG were administered. A low dose of 1 X 10(3) c.p. of BCG induced a positive PPD skin reaction in 2 of 4 animals after six BCG instillations. After six BCG instillation BCG immune lymphocytes were present both in the iliac lymph nodes and in the spleen. No differences in mitogenic responses to ConA, PHA and LPS were observed in iliac lymph nodes or the spleen between placebo or BCG treated animals. In the regional iliac lymph nodes a significantly increased number of leukocytes was present. These lymph node cells showed a significant increase in the expression of MHC class II (Ia) immune response antigen on their surface. In the spleen no differences were observed after BCG administration regarding the number of cells present and in terms of the Ia antigen expression of the leukocytes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2922891     DOI: 10.1007/BF00261051

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  38 in total

1.  The granulomatous inflammatory response. A review.

Authors:  D O Adams
Journal:  Am J Pathol       Date:  1976-07       Impact factor: 4.307

2.  Histopathology of BCG and thiotepa treated bladders.

Authors:  P Guinan; M Shaw; V Ray
Journal:  Urol Res       Date:  1986

Review 3.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

4.  Tumor regression mediated by Mycobacterium bovis (strain BCG). Effects of isonicotinic acid hydrazide, cortisone acetate, and antithymocyte serum.

Authors:  E B Chung; B Zbar; H J Rapp
Journal:  J Natl Cancer Inst       Date:  1973-07       Impact factor: 13.506

5.  Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer.

Authors:  J M Lage; W C Bauer; D R Kelley; T L Ratliff; W J Catalona
Journal:  J Urol       Date:  1986-05       Impact factor: 7.450

6.  Antitumor immunity, V.BCG-induced growth inhibition of murine tumors. Effect of hydrocortisone, antiserum against theta antigen, and gamma-irradiated BCG.

Authors:  P K Ray; T B Poduval; K Sundaram
Journal:  J Natl Cancer Inst       Date:  1977-03       Impact factor: 13.506

Review 7.  Immunotherapy of superficial bladder cancer.

Authors:  A Shapiro; D Kadmon; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1982-11       Impact factor: 7.450

8.  Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches.

Authors:  W H de Jong; P A Steerenberg; J G Kreeftenberg; R H Tiesjema; W Kruizinga; L M van Noorle Jansen; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer.

Authors:  T L Ratliff; E O Haaff; W J Catalona
Journal:  Clin Immunol Immunopathol       Date:  1986-08

10.  Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

Authors:  D L Lamm; D E Thor; S C Harris; J A Reyna; V D Stogdill; H M Radwin
Journal:  J Urol       Date:  1980-07       Impact factor: 7.450

View more
  4 in total

1.  Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder.

Authors:  L T Balemans; P D Vegt; P A Steerenberg; E C De Boer; A Van Swaaij; R E De Vries; A P Van der Meijden; W Den Otter
Journal:  Urol Res       Date:  1994

2.  Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin.

Authors:  W H De Jong; E C De Boer; A P Van der Meijden; P Vegt; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.

Authors:  E C De Boer; W H De Jong; A P Van Der Meijden; P A Steerenberg; J A Witjes; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Interaction between bacteria and the lumenal bladder surface: modulation by pentosan polysulfate, an experimental and theoretical approach with clinical implication.

Authors:  D H Schamhart; E C de Boer; K H Kurth
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.